In October 2021, the US Food and Drug Administration (FDA) approved Susvimo ® (ranibizumab injection; Genentech, Inc.) for intravitreal use via the Susvimo ocular implant for the treatment of patients ...

Variation is seen in preparedness and response to highly pathogenic avian influenza (HPAI) A(H5N1) viruses. HealthDay News — Variation is seen in preparedness and response to highly pathogenic avian ...

Comprehensive staging of diabetic macular edema using the ESASO classification method more accurately predicts outcomes of the disease in comparison to individual biomarkers. The European School of ...

Anti-VEGF injections delivered on a treat-and-extend basis produce superior visual acuity outcomes. Patients with diabetic macular edema (DME) who are treated with a proactive treat-and-extend (T&E) ...

There is a 97.5% chance that the OSPREY trial will successfully demonstrate that the AHI responder rate of patients with OSA with device stimulation activated is higher than of those without ...

Black patients with non-arteritic anterior ischemic optic neuropathy experience referral delay, and are less likely to have hypothyroidism but more likely to have chronic kidney disease and dialysis ...

Accumulation of vitelliform material and ischemic factors have shown to be related to atrophic progression of acquired vitellifrom lesions. Acquired vitelliform lesion (AVL) height and the presence of ...

PHOMS are more prevalent in patients with syndromic craniosynostosis than other patients, and are associated with a history of intracranial hypertension and papilledema. Peripapillary hyperreflective ...

Risk factors for distal symmetric polyneuropathy included a type 2 diabetes diagnosis and increased diabetes duration. Patients with longer diabetes duration and higher glycemic exposure have a ...

Systemic allergies and ulcerative colitis may increase susceptibility to keratoconus. Patients who have systemic allergies and other systemic diseases appear to have high susceptibility to keratoconus ...

Teprotumumab can significantly improve diplopia in thyroid eye disease, particiularly in patients with recent onset and high inflammation. Teprotumumab significantly improves diplopia in patients with ...